ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2620

Transition Success of Pediatric Rheumatology Patients: A Novel Scoring System

Kyla Blasingame1, David McDonald1, Karissa Chesky1, Jimin Kim1, charles lee1, Constance Wiemann1, Blanca Sanchez-Fournier1, Miriah Gillispie-Taylor2 and Tiphanie Vogel1, 1Baylor College of Medicine, Houston, TX, 2Baylor College of Medicine/Texas Children's Hospital, Houston, TX

Meeting: ACR Convergence 2025

Keywords: Outcome measures, quality of care

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: Abstracts: Measures & Measurement of Healthcare Quality (2615–2620)

Session Type: Abstract Session

Session Time: 4:15PM-4:30PM

Background/Purpose: Success of transition from pediatric to adult care depends on many factors. Various scores for transition readiness have been developed, including some designed to capture patient self-reported readiness and others that focus on program specific parameters. However, few patient-level transition success scores exist. Without such a score, it is difficult to assess the impact of programmatic interventions to improve the process of transition on transition outcomes. We created a novel transition success score for pediatric rheumatology patients.

Methods: Pediatric rheumatologists and adolescent health experts were consulted. Four components were included in the score: attending the first adult appointment in the time frame designated by the pediatric rheumatologist (component 1), refilling medications within 3 months of the first adult appointment (component 2), attending a second adult appointment (component 3), and no rheumatology-related emergency department visits in the first year after transition (component 4). Scores were determined via electronic medical record (EMR) review. Each component was weighted as one-quarter of the total transition success score. The few patients who transitioned off medications were scored successfully for component 2.

Results: From 2017-2024, we identified 357 patients with a final visit to pediatric rheumatology using direct provider notification of transition to adult rheumatology clinic and EMR review. Of those, 199 were able to be scored for transition success. Some patients were unable to be scored due to subsequent healthcare details being inaccessible via EMR (n=73), others because it was still < 1 year since the final pediatric appointment (n=59), and others for various reasons such as dismissal from the need for future rheumatology followup (n=26). The average age at transition was 18.6 years. 73/199 (37%) patients scored 100 (ie achieved all 4 components of successful transition) and 77/199 (39%) scored 75. Only 3 patients (1.5%) scored 0. The average score was 74.3%. When considered by component, 114 patients (57%) met component 1, 151 (76%) met component 2, 160 (80%) met component 3, and 166 (83%) met component 4.

Conclusion: We developed a transition success score and applied it to patients who had transitioned from our pediatric rheumatology clinic. Although 150/199 patients (75%) fulfilled 3 or 4 out of 4 components of successful transition, we were unable to document attendance at a second adult rheumatology appointment for a surprising 20% of transitioned patients. Our next steps include correlating components of our transition program, including demographics, transition planning, self-reported transition readiness, and receipt of a transition summary letter, with the transition success score to better understand what factors predict successful transition.


Disclosures: K. Blasingame: None; D. McDonald: None; K. Chesky: None; J. Kim: None; c. lee: None; C. Wiemann: None; B. Sanchez-Fournier: None; M. Gillispie-Taylor: None; T. Vogel: AstraZeneca, 5, moderna, 2, Pfizer, 2, SOBI, 1, 2, takeda, 6.

To cite this abstract in AMA style:

Blasingame K, McDonald D, Chesky K, Kim J, lee c, Wiemann C, Sanchez-Fournier B, Gillispie-Taylor M, Vogel T. Transition Success of Pediatric Rheumatology Patients: A Novel Scoring System [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/transition-success-of-pediatric-rheumatology-patients-a-novel-scoring-system/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/transition-success-of-pediatric-rheumatology-patients-a-novel-scoring-system/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology